Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels

M. G. Mainwaring, Lisa M Rimsza, S. F. Chen, S. P. Gomez, F. W. Weeks, V. Reddy, J. Lynch, W. S. May, S. Kahn, J. Moreb, H. Leather, R. Braylan, T. C. Rowe, K. J. Finiewicz, J. R. Wingard

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the topoisomerase II-inhibitors, etoposide+mitoxantrone (T-EM) treatment is proposed to induce topoisomerase II protein levels and potentiate the cytotoxic activity of the topoisomerase II-directed drugs. Fourteen patients had refractory and three had recurrent acute leukemia. The majority of patients were heavily pre-treated with greater than three re-induction chemotherapy regimens. Ten patients responded to T-EM treatment (59%). Four of seventeen (24%) had a complete remission and one had a partial remission. Four additional patients (24%) who scored complete leukemia clearance had no evidence of disease with complete white and red blood cell recovery but with platelet counts less than 100,000. The lack of platelet recovery in one patient having a partial response was scored as a partial leukemia clearance. The toxicity profile included major nonhematological toxicity including grade 3 mucositis (29%) and neutropenic fever (65%). Paired measurements of intracellular levels of topoisomerase II isoforms α and β in leukemia blast cells (bone marrow) collected before (day 0) and after topotecan treatment (day 4) showed that a relative increase of topoisomerase IIα (Topo IIα) ≥40% strongly correlated with response after T-EM treatment. Increased Topo IIα levels also corresponded to increased DNA fragmentation. Two patients who had an increase of Topo IIα of 20-25% had either a PR or PLC while patients with a < 10% increase showed no response to T-EM treatment. We conclude that timed sequential chemotherapy using topotecan followed by etoposide+mitoxantrone is an effective regimen for patients with refractory acute leukemia, and demonstrate Topo IIα protein level increases after topotecan treatment.

Original languageEnglish (US)
Pages (from-to)989-999
Number of pages11
JournalLeukemia and Lymphoma
Volume43
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Topoisomerase II Inhibitors
Topotecan
Mitoxantrone
Type II DNA Topoisomerase
Etoposide
Leukemia
Drug Therapy
Therapeutics
Topoisomerase I Inhibitors
Mucositis
Induction Chemotherapy
DNA Fragmentation
Platelet Count
Bone Marrow Cells
Protein Isoforms
Proteins
Leukocytes
Fever
Blood Platelets
Erythrocytes

Keywords

  • Refractory acute leukemia
  • Sequential chemotherapy
  • Topoisomerase II
  • Topotecan

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. / Mainwaring, M. G.; Rimsza, Lisa M; Chen, S. F.; Gomez, S. P.; Weeks, F. W.; Reddy, V.; Lynch, J.; May, W. S.; Kahn, S.; Moreb, J.; Leather, H.; Braylan, R.; Rowe, T. C.; Finiewicz, K. J.; Wingard, J. R.

In: Leukemia and Lymphoma, Vol. 43, No. 5, 2002, p. 989-999.

Research output: Contribution to journalArticle

Mainwaring, MG, Rimsza, LM, Chen, SF, Gomez, SP, Weeks, FW, Reddy, V, Lynch, J, May, WS, Kahn, S, Moreb, J, Leather, H, Braylan, R, Rowe, TC, Finiewicz, KJ & Wingard, JR 2002, 'Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels', Leukemia and Lymphoma, vol. 43, no. 5, pp. 989-999. https://doi.org/10.1080/10428190290021339
Mainwaring, M. G. ; Rimsza, Lisa M ; Chen, S. F. ; Gomez, S. P. ; Weeks, F. W. ; Reddy, V. ; Lynch, J. ; May, W. S. ; Kahn, S. ; Moreb, J. ; Leather, H. ; Braylan, R. ; Rowe, T. C. ; Finiewicz, K. J. ; Wingard, J. R. / Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 5. pp. 989-999.
@article{82e5c84bab9c4d41a92efbea1d62db2c,
title = "Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels",
abstract = "A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the topoisomerase II-inhibitors, etoposide+mitoxantrone (T-EM) treatment is proposed to induce topoisomerase II protein levels and potentiate the cytotoxic activity of the topoisomerase II-directed drugs. Fourteen patients had refractory and three had recurrent acute leukemia. The majority of patients were heavily pre-treated with greater than three re-induction chemotherapy regimens. Ten patients responded to T-EM treatment (59{\%}). Four of seventeen (24{\%}) had a complete remission and one had a partial remission. Four additional patients (24{\%}) who scored complete leukemia clearance had no evidence of disease with complete white and red blood cell recovery but with platelet counts less than 100,000. The lack of platelet recovery in one patient having a partial response was scored as a partial leukemia clearance. The toxicity profile included major nonhematological toxicity including grade 3 mucositis (29{\%}) and neutropenic fever (65{\%}). Paired measurements of intracellular levels of topoisomerase II isoforms α and β in leukemia blast cells (bone marrow) collected before (day 0) and after topotecan treatment (day 4) showed that a relative increase of topoisomerase IIα (Topo IIα) ≥40{\%} strongly correlated with response after T-EM treatment. Increased Topo IIα levels also corresponded to increased DNA fragmentation. Two patients who had an increase of Topo IIα of 20-25{\%} had either a PR or PLC while patients with a < 10{\%} increase showed no response to T-EM treatment. We conclude that timed sequential chemotherapy using topotecan followed by etoposide+mitoxantrone is an effective regimen for patients with refractory acute leukemia, and demonstrate Topo IIα protein level increases after topotecan treatment.",
keywords = "Refractory acute leukemia, Sequential chemotherapy, Topoisomerase II, Topotecan",
author = "Mainwaring, {M. G.} and Rimsza, {Lisa M} and Chen, {S. F.} and Gomez, {S. P.} and Weeks, {F. W.} and V. Reddy and J. Lynch and May, {W. S.} and S. Kahn and J. Moreb and H. Leather and R. Braylan and Rowe, {T. C.} and Finiewicz, {K. J.} and Wingard, {J. R.}",
year = "2002",
doi = "10.1080/10428190290021339",
language = "English (US)",
volume = "43",
pages = "989--999",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels

AU - Mainwaring, M. G.

AU - Rimsza, Lisa M

AU - Chen, S. F.

AU - Gomez, S. P.

AU - Weeks, F. W.

AU - Reddy, V.

AU - Lynch, J.

AU - May, W. S.

AU - Kahn, S.

AU - Moreb, J.

AU - Leather, H.

AU - Braylan, R.

AU - Rowe, T. C.

AU - Finiewicz, K. J.

AU - Wingard, J. R.

PY - 2002

Y1 - 2002

N2 - A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the topoisomerase II-inhibitors, etoposide+mitoxantrone (T-EM) treatment is proposed to induce topoisomerase II protein levels and potentiate the cytotoxic activity of the topoisomerase II-directed drugs. Fourteen patients had refractory and three had recurrent acute leukemia. The majority of patients were heavily pre-treated with greater than three re-induction chemotherapy regimens. Ten patients responded to T-EM treatment (59%). Four of seventeen (24%) had a complete remission and one had a partial remission. Four additional patients (24%) who scored complete leukemia clearance had no evidence of disease with complete white and red blood cell recovery but with platelet counts less than 100,000. The lack of platelet recovery in one patient having a partial response was scored as a partial leukemia clearance. The toxicity profile included major nonhematological toxicity including grade 3 mucositis (29%) and neutropenic fever (65%). Paired measurements of intracellular levels of topoisomerase II isoforms α and β in leukemia blast cells (bone marrow) collected before (day 0) and after topotecan treatment (day 4) showed that a relative increase of topoisomerase IIα (Topo IIα) ≥40% strongly correlated with response after T-EM treatment. Increased Topo IIα levels also corresponded to increased DNA fragmentation. Two patients who had an increase of Topo IIα of 20-25% had either a PR or PLC while patients with a < 10% increase showed no response to T-EM treatment. We conclude that timed sequential chemotherapy using topotecan followed by etoposide+mitoxantrone is an effective regimen for patients with refractory acute leukemia, and demonstrate Topo IIα protein level increases after topotecan treatment.

AB - A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the topoisomerase II-inhibitors, etoposide+mitoxantrone (T-EM) treatment is proposed to induce topoisomerase II protein levels and potentiate the cytotoxic activity of the topoisomerase II-directed drugs. Fourteen patients had refractory and three had recurrent acute leukemia. The majority of patients were heavily pre-treated with greater than three re-induction chemotherapy regimens. Ten patients responded to T-EM treatment (59%). Four of seventeen (24%) had a complete remission and one had a partial remission. Four additional patients (24%) who scored complete leukemia clearance had no evidence of disease with complete white and red blood cell recovery but with platelet counts less than 100,000. The lack of platelet recovery in one patient having a partial response was scored as a partial leukemia clearance. The toxicity profile included major nonhematological toxicity including grade 3 mucositis (29%) and neutropenic fever (65%). Paired measurements of intracellular levels of topoisomerase II isoforms α and β in leukemia blast cells (bone marrow) collected before (day 0) and after topotecan treatment (day 4) showed that a relative increase of topoisomerase IIα (Topo IIα) ≥40% strongly correlated with response after T-EM treatment. Increased Topo IIα levels also corresponded to increased DNA fragmentation. Two patients who had an increase of Topo IIα of 20-25% had either a PR or PLC while patients with a < 10% increase showed no response to T-EM treatment. We conclude that timed sequential chemotherapy using topotecan followed by etoposide+mitoxantrone is an effective regimen for patients with refractory acute leukemia, and demonstrate Topo IIα protein level increases after topotecan treatment.

KW - Refractory acute leukemia

KW - Sequential chemotherapy

KW - Topoisomerase II

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=18344395132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344395132&partnerID=8YFLogxK

U2 - 10.1080/10428190290021339

DO - 10.1080/10428190290021339

M3 - Article

C2 - 12148910

AN - SCOPUS:18344395132

VL - 43

SP - 989

EP - 999

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -